Posted by Michael Wonder on 16 May 2025
FDA approves retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal
15 May 2025 - Today, the FDA approved retifanlimab-dlwr (Zynyz, Incyte) with carboplatin and paclitaxel for the first-line treatment of adults with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.
The FDA also approved retifanlimab-dlwr, as a single agent, for adults with locally recurrent or metastatic squamous cell carcinoma of the anal canal. with disease progression on or intolerance to platinum-based chemotherapy.
